Publication at First Faculty of Medicine |
2009
Abstract
Dyslipidaemias and hyperlipoproteinemias (DLP and HLP) represent one from the most important risk factors for atherosclerosis development and for cardiovascular diseases in general. Treatment of HLP/DLP is based on recent guidelines and includes both, non - pharmacological and pharmacological treatment.
Pharmacological manegment of dyslipidemia represent several classes of lipid lowering drugs: Statins,fibrates, nicotinic acid, ezetimibe (inhibitor of cholesterol absorption in the intestine) and resins.